Zosano Announces Results of Special Meeting of Stockholders and 1-for-20 Reverse Stock Split

Zosano Pharma (NASDAQ:ZSAN) a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary ADAM technology, today announced the results of the special meeting of stockholders held on January 23, 2018 and that the Company will effect a reverse stock split of its issued and outstanding common stock.
As quoted in the press release:

Following the special meeting of stockholders, the Company’s Board of Directors approved the implementation of a reverse stock split, determined the appropriate reverse stock split to be a ratio of 1-for-20 and approved the filing of a Certificate of Amendment to the Restated Certificate of Incorporation of the Company to effectuate the reverse stock split.

Click here for the full press release.